ITMI20031023A1 - Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. - Google Patents

Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.

Info

Publication number
ITMI20031023A1
ITMI20031023A1 IT001023A ITMI20031023A ITMI20031023A1 IT MI20031023 A1 ITMI20031023 A1 IT MI20031023A1 IT 001023 A IT001023 A IT 001023A IT MI20031023 A ITMI20031023 A IT MI20031023A IT MI20031023 A1 ITMI20031023 A1 IT MI20031023A1
Authority
IT
Italy
Prior art keywords
treatment
molecular weight
average molecular
glycosaminoglicans
emotional dysfunctions
Prior art date
Application number
IT001023A
Other languages
English (en)
Inventor
Umberto Cornelli
Ambrosi Luigi De
Jawed Fareed
Israel Hanin
John Lee
Stanley Lorens
Ron Mervis
Original Assignee
Umberto Cornelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umberto Cornelli filed Critical Umberto Cornelli
Priority to IT001023A priority Critical patent/ITMI20031023A1/it
Publication of ITMI20031023A0 publication Critical patent/ITMI20031023A0/it
Priority to CA002526201A priority patent/CA2526201A1/en
Priority to EP04741606A priority patent/EP1631298B8/en
Priority to DK04741606T priority patent/DK1631298T3/da
Priority to PT04741606T priority patent/PT1631298E/pt
Priority to AU2004241748A priority patent/AU2004241748B2/en
Priority to HK06104250.1A priority patent/HK1084023B/en
Priority to SI200430547T priority patent/SI1631298T1/sl
Priority to RU2005138517/15A priority patent/RU2353371C2/ru
Priority to JP2006530208A priority patent/JP4757197B2/ja
Priority to DE602004009068T priority patent/DE602004009068T2/de
Priority to PL04741606T priority patent/PL1631298T3/pl
Priority to KR1020057021781A priority patent/KR20060025142A/ko
Priority to PCT/EP2004/050860 priority patent/WO2004103381A1/en
Priority to NZ544238A priority patent/NZ544238A/en
Priority to AT04741606T priority patent/ATE373480T1/de
Priority to CNB2004800136097A priority patent/CN100377717C/zh
Priority to ES04741606T priority patent/ES2294507T3/es
Priority to US10/557,860 priority patent/US7812005B2/en
Publication of ITMI20031023A1 publication Critical patent/ITMI20031023A1/it
Priority to IL171981A priority patent/IL171981A/en
Priority to ZA200510132A priority patent/ZA200510132B/en
Priority to NO20056089A priority patent/NO20056089L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
IT001023A 2003-05-21 2003-05-21 Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. ITMI20031023A1 (it)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IT001023A ITMI20031023A1 (it) 2003-05-21 2003-05-21 Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
US10/557,860 US7812005B2 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treatment of emotional dysfunctions
DE602004009068T DE602004009068T2 (de) 2003-05-21 2004-05-19 Glycosaminoglykane zur behandlung emotionaler störungen
KR1020057021781A KR20060025142A (ko) 2003-05-21 2004-05-19 정서 기능장애 치료용 글리코사미노글리칸
DK04741606T DK1631298T3 (da) 2003-05-21 2004-05-19 Glykosaminoglykaner til behandling af emotionelle funktionsforstyrrelser
PT04741606T PT1631298E (pt) 2003-05-21 2004-05-19 Glicosaminoglicanos destinados ao tratamento das disfunções emocionais
AU2004241748A AU2004241748B2 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treatment emotional dysfunctions
HK06104250.1A HK1084023B (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treating emotional dysfunctions
SI200430547T SI1631298T1 (sl) 2003-05-21 2004-05-19 Glikozaminglikani za zdravljenje emocionalnih disfunkcij
RU2005138517/15A RU2353371C2 (ru) 2003-05-21 2004-05-19 Гликозаминогликаны для лечения эмоциональных дисфункций
JP2006530208A JP4757197B2 (ja) 2003-05-21 2004-05-19 情緒障害処置用グリコサミノグリカン
CA002526201A CA2526201A1 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treatment emotional dysfunctions
PL04741606T PL1631298T3 (pl) 2003-05-21 2004-05-19 Glikozaminoglikany do leczenia zaburzeń emocjonalnych
EP04741606A EP1631298B8 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treating emotional dysfunctions
PCT/EP2004/050860 WO2004103381A1 (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treatment emotional dysfunctions
NZ544238A NZ544238A (en) 2003-05-21 2004-05-19 Glycosaminoglycans for treatment emotional dysfunctions
AT04741606T ATE373480T1 (de) 2003-05-21 2004-05-19 Glycosaminoglykane zur behandlung emotionaler störungen
CNB2004800136097A CN100377717C (zh) 2003-05-21 2004-05-19 用于治疗情绪功能障碍的糖胺聚糖
ES04741606T ES2294507T3 (es) 2003-05-21 2004-05-19 Glicosaminoglicanos para el ratamiento e disfunciones emocionales.
IL171981A IL171981A (en) 2003-05-21 2005-11-15 Glycosaminoglycans for treatment of emotional dysfunctions
ZA200510132A ZA200510132B (en) 2003-05-21 2005-12-13 Glycosaminoglycans for treatment of emotional dysfunctions
NO20056089A NO20056089L (no) 2003-05-21 2005-12-21 Glykosaminoglykaner for behandling av emosjonelle dysfunksjoner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001023A ITMI20031023A1 (it) 2003-05-21 2003-05-21 Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.

Publications (2)

Publication Number Publication Date
ITMI20031023A0 ITMI20031023A0 (it) 2003-05-21
ITMI20031023A1 true ITMI20031023A1 (it) 2004-11-22

Family

ID=30131059

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001023A ITMI20031023A1 (it) 2003-05-21 2003-05-21 Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.

Country Status (20)

Country Link
US (1) US7812005B2 (it)
EP (1) EP1631298B8 (it)
JP (1) JP4757197B2 (it)
KR (1) KR20060025142A (it)
CN (1) CN100377717C (it)
AT (1) ATE373480T1 (it)
AU (1) AU2004241748B2 (it)
CA (1) CA2526201A1 (it)
DE (1) DE602004009068T2 (it)
DK (1) DK1631298T3 (it)
ES (1) ES2294507T3 (it)
IL (1) IL171981A (it)
IT (1) ITMI20031023A1 (it)
NO (1) NO20056089L (it)
NZ (1) NZ544238A (it)
PL (1) PL1631298T3 (it)
PT (1) PT1631298E (it)
RU (1) RU2353371C2 (it)
WO (1) WO2004103381A1 (it)
ZA (1) ZA200510132B (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584704B (zh) * 2008-05-23 2010-12-15 鲁南制药集团股份有限公司 肝素、低分子肝素可药用盐或其衍生物的医药用途
CN106282122B (zh) * 2016-08-23 2020-10-02 中国科学院上海药物研究所 一种非人哺乳动物恐惧症或其相关疾病动物模型的建立方法及其用途
CN112438991B (zh) * 2019-08-29 2024-03-15 鲁南制药集团股份有限公司 肝素、或其衍生物、或其可药用盐的医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4916219A (en) * 1985-03-28 1990-04-10 University Of Iowa Research Foundation Oligosaccharide heparin fragments as inhibitors of complement cascade
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
FR2763848B1 (fr) * 1997-05-28 2000-01-28 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central
FR2763849B1 (fr) * 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
JP4412756B2 (ja) * 1998-02-26 2010-02-10 生化学工業株式会社 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile

Also Published As

Publication number Publication date
JP4757197B2 (ja) 2011-08-24
ITMI20031023A0 (it) 2003-05-21
DE602004009068T2 (de) 2008-06-19
NZ544238A (en) 2008-08-29
WO2004103381A1 (en) 2004-12-02
DK1631298T3 (da) 2008-01-28
CA2526201A1 (en) 2004-12-02
CN100377717C (zh) 2008-04-02
US7812005B2 (en) 2010-10-12
RU2353371C2 (ru) 2009-04-27
PT1631298E (pt) 2007-12-31
JP2006528670A (ja) 2006-12-21
KR20060025142A (ko) 2006-03-20
PL1631298T3 (pl) 2008-04-30
IL171981A (en) 2010-04-15
RU2005138517A (ru) 2006-08-27
HK1084023A1 (en) 2006-07-21
IL171981A0 (en) 2006-04-10
EP1631298B1 (en) 2007-09-19
DE602004009068D1 (de) 2007-10-31
ZA200510132B (en) 2006-08-30
ES2294507T3 (es) 2008-04-01
AU2004241748B2 (en) 2010-05-13
AU2004241748A1 (en) 2004-12-02
NO20056089L (no) 2006-02-09
EP1631298A1 (en) 2006-03-08
US20060205690A1 (en) 2006-09-14
ATE373480T1 (de) 2007-10-15
EP1631298B8 (en) 2008-12-24
CN1791416A (zh) 2006-06-21

Similar Documents

Publication Publication Date Title
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
DE602004022316D1 (de) Legierungszusammensetzungen und diese enthaltende vorrichtungen
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
CY1106894T1 (el) Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0411528A (pt) uso de isomalte como prebiótico
WO2007022380A3 (en) Bis-aryl amide compounds and methods of use
DE602005002562D1 (de) Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
EP2037739A4 (en) BENZYL-SUBSTITUTED POSITIVE ALLOSTERIC CHINOLON M1 RECEPTOR MODULATORS
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
SE0301653D0 (sv) Novel compounds
CY1110316T1 (el) Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους
AR071120A1 (es) Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
EA200601462A1 (ru) Соединения для лечения заболеваний
EA200702253A1 (ru) Фармацевтическая композиция
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
EP2402321A3 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
ITMI20031023A1 (it) Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.